Evidence map›Paper›PMID 21714556›Full record

ArticleJournal of the American Chemical Society2011

Chemical synthesis enables biochemical and antibacterial evaluation of streptolydigin antibiotics.

Sergey V Pronin, Anthony Martinez, Konstantin Kuznedelov, Konstantin Severinov, Howard A Shuman, Sergey A Kozmin

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Mycobacterium tuberculosis is resistant to streptolydigin.Tuberculosis (Edinburgh, Scotland) · 2013
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sergey V ProninDepartment of Chemistry, University of Chicago, Chicago, Illinois 60607, USA.
Anthony Martinez
Konstantin Kuznedelov
Konstantin Severinov
Howard A Shuman
Sergey A Kozmin
Institute of Gene Biology · RURutgers, The State University of New Jersey · US

Funding

Predoctoral Training Program in Chemistry & BiologyT32GM008720 · NIGMS · UNIVERSITY OF CHICAGO · PI PICCIRILLI, JOSEPH ANTHONY · 1999 to 2020
$4.7M
Structure-based mutational analysis of RNA polymeraseR01GM064530 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI SEVERINOV, KONSTANTIN V · 2002 to 2010
$2.7M
Unusual RNA polymerase from pathogenic bacterium Francisella tularensisR21AI090558 · NIAID · RUTGERS, THE STATE UNIV OF N.J. · PI KUZNEDELOV, KONSTANTIN · 2010 to 2011
$421k
NIAID NIH HHS AI090558NIAID NIH HHS R21 AI090558NIGMS NIH HHS GM64530NIGMS NIH HHS R01 GM064530NIGMS NIH HHS T32 GM008720
6 · The paper itself

Abstract

Inhibition of bacterial transcription represents an effective and clinically validated anti-infective chemotherapeutic strategy. We describe the evolution of our approach to the streptolydigin class of antibiotics that target bacterial RNA polymerases (RNAPs). This effort resulted in the synthesis and biological evaluation of streptolydigin, streptolydiginone, streptolic acid, and a series of new streptolydigin-based agents. Subsequent biochemical evaluation of RNAP inhibition demonstrated that the presence of both streptolic acid and tetramic acid subunits was required for activity of this class of antibiotics. In addition, we identified 10,11-dihydrostreptolydigin as a new RNAP-targeting agent, which was assembled with high synthetic efficiency of 15 steps in the longest linear sequence. Dihydrostreptolydigin inhibited three representative bacterial RNAPs and displayed in vitro antibacterial activity against S. salivarius . The overall increase in synthetic efficiency combined with substantial antibacterial activity of this fully synthetic antibiotic demonstrates the power of organic synthesis in enabling design and comprehensive in vitro pharmacological evaluation of new chemical agents that target bacterial transcription.

Indexed as

AminoglycosidesAnti-Bacterial AgentsDNA-Directed RNA PolymerasesDose-Response Relationship, DrugDrug DesignEnzyme InhibitorsMicrobial Sensitivity TestsMolecular StructureStreptococcusStructure-Activity RelationshipThermusAminoglycosidesAnti-Bacterial AgentsDNA-Directed RNA PolymerasesEnzyme Inhibitorsstreptolydigin

Identifiers

PMID21714556
PMCPMC3174773
OpenAlexW2148761510

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.